The Effect of Curcumin Supplementation on Recovery From Exercise-induced Muscle Damage

Recent evidence suggests that curcumin supplementation may reduce muscle inflammation, oxidative markers, and muscle damage. The most favourable dosage to elicit these ergogenic effects are yet to be established; both 750mg & 1500mg has been shown to be effective. Curcumin supplementation has been ingested in numerous different ways however, no previous research to date has used curcumin in a hydrolysed (drinkable) format. The aim of this study is to investigate whether hydrolysed curcumin can reduce indices of muscle damage and improve recovery, whilst also examining a potential dose-response effect.

Study Overview

• Status: Not yet recruiting
• Conditions: Exercise Induced Muscle Damage
• Intervention / Treatment: Dietary supplement: Curcumin

• Study Type: Interventional
• Enrollment (Anticipated): 36
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Luke Hughes, PhD; Phone Number: +447920004214; Email: luke4.hughes@northumbria.ac.uk
• Study Contact Backup: Name: Ian Grant, MSc; Phone Number: 020 8240 4000; Email: ian.grant@stmarys.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Inclusion criteria are as follows:

• between the age of 18-35
• non-smoker
• no previous history of cardiovascular, respiratory, or neurological problems
• not taking anticoagulant medication
• injury-free in the 3 months prior to scheduled participation in the study

Exclusion Criteria:

Exclusion criteria include:

• hypertension (<140/80)
• any blood diseases or clotting issues,
• injury, or previous injury in <3 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Curcumin Single; The Single dose group will consume 1 placebo sachet and one curcumin sachet per day. Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format. The placebo is a sachet containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format. Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm).	Dietary supplement: Curcumin; Curcumin Supplementation
Experimental: Curcumin Double; The double dose group will consume two sachets per day of curcumin. Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format. Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm).	Dietary supplement: Curcumin; Curcumin Supplementation
No Intervention: Placebo; Placebo sachets containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format. Participants will consume two sachets per day. Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood markers	Blood samples will be taken for analysis of markers of IL-6, IL-1β, TNF-α, IL-1, IL-4, IL-10 and CK will be taken	Baseline
Blood markers	Blood samples will be taken for analysis of markers of IL-6, IL-1β, TNF-α, IL-1, IL-4, IL-10 and CK will be taken	immediately post muscle damage intervention
Blood markers	Blood samples will be taken for analysis of markers of IL-6, IL-1β, TNF-α, IL-1, IL-4, IL-10 and CK will be taken	24 hours post
Blood markers	Blood samples will be taken for analysis of markers of IL-6, IL-1β, TNF-α, IL-1, IL-4, IL-10 and CK will be taken	48 hours post
Blood markers	Blood samples will be taken for analysis of markers of IL-6, IL-1β, TNF-α, IL-1, IL-4, IL-10 and CK will be taken	72 hours post
Ford and Fort	Capillary sample Ford and Fort tests	Baseline
Ford and Fort	Capillary sample Ford and Fort tests	Immediately post muscle damage intervention
Ford and Fort	Capillary sample Ford and Fort tests	24 hours post
Ford and Fort	Capillary sample Ford and Fort tests	48 hours post
Ford and Fort	Capillary sample Ford and Fort tests	72 hours post
Soreness	Perceived muscle soreness scale - Visual analouge scale	Baseline
Soreness	Perceived muscle soreness scale - Visual analouge scale	Immediately post muscle damage intervention
Soreness	Perceived muscle soreness scale - Visual analouge scale	24 hours post
Soreness	Perceived muscle soreness scale - Visual analouge scale	48 hours post
Soreness	Perceived muscle soreness scale - Visual analouge scale	72 hours post
Soreness	BORG CR-10 scale	Baseline
Soreness	BORG CR-10 scale	Immediately post muscle damage intervention
Soreness	BORG CR-10 scale	24 hours post
Soreness	BORG CR-10 scale	48 hours post
Soreness	BORG CR-10 scale	72 hours post
Soreness	Pressure pain threshold	Baseline
Soreness	Pressure pain threshold	Immediately post muscle damage intervention
Soreness	Pressure pain threshold	24 hours post
Soreness	Pressure pain threshold	48 hours post
Soreness	Pressure pain threshold	72 hours post
Muscle Structure	Muscle swelling - thigh girth + Ultrasound measurement	Baseline
Muscle Structure	Muscle swelling - thigh girth + Ultrasound measurement	Immediately post muscle damage intervention
Muscle Structure	Muscle swelling - thigh girth + Ultrasound measurement	24 hours post
Muscle Structure	Muscle swelling - thigh girth + Ultrasound measurement	48 hours post
Muscle Structure	Muscle swelling - thigh girth + Ultrasound measurement	72 hours post
Muscle Function	maximal strength	Baseline
Muscle Function	maximal strength	Immediately post muscle damage intervention
Muscle Function	maximal strength	24 hours post
Muscle Function	maximal strength	48 hours post
Muscle Function	maximal strength	72 hours post
Muscle Function	Muscular endurance	Baseline
Muscle Function	Muscular endurance	Immediately post muscle damage intervention
Muscle Function	Muscular endurance	24 hours post
Muscle Function	Muscular endurance	48 hours post
Muscle Function	Muscular endurance	72 hours post

Collaborators and Investigators

• Sponsor: St Mary's University College
• Investigators: Principal Investigator: Luke Hughes, PhD, Northumbria University; Principal Investigator: Jess Hill, PhD, St. Mary's University, Twickenham

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2022
• Primary Completion (Anticipated): September 30, 2022
• Study Completion (Anticipated): September 30, 2023

Study Registration Dates

• First Submitted: April 12, 2022
• First Submitted That Met QC Criteria: April 19, 2022
• First Posted (Actual): April 26, 2022

Study Record Updates

• Last Update Posted (Actual): April 26, 2022
• Last Update Submitted That Met QC Criteria: April 19, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Curcumin
• Other Study ID Numbers: ASE22HELCON

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No